OR5B3

Across TCGA pan-cancer cohorts, OR5B3 Mutation is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated OR5B3 data layer compared with 6 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher OR5B3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR5B3 expression acts as an unfavorable survival marker, although some lineages such as SKCM and COAD show a favorable association.

SCLC, STAD, and LIHC are the cancer types where OR5B3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.708	<.001	36	view →
STAD	OS	Median	All	0.228	0.729	.010	18	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
LUSC	OS	Median	All	0.555	0.780	.018	8	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.581	0.211	.034	2	view →
COAD	DFS	Median	All	1.000	0.497	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

OR5B3–SCLC (OS)

Open the SCLC breakdown →